<DOC>
	<DOCNO>NCT01278394</DOCNO>
	<brief_summary>The purpose study determine safety efficacy 5.0 % AN2690 Solution treatment distal , subungual onychomycosis great target toenail .</brief_summary>
	<brief_title>Safety Efficacy Study Subjects With Onychomycosis Great Toenail</brief_title>
	<detailed_description>In cohort , target great toenail identify Baseline prior commencement treatment culture result collect Screening visit evaluate primary efficacy whereas treat toenail evaluate safety . At visit , investigator ask make clinical evaluation target great nail , mark whether consider nail clear onychomycosis . This evaluation basis determine whether study medication dispense visit . This record include information Cohort 3 ( 5 % solution ) study . Cohorts 1 2 , describe NCT00679523 ( 7.5 % solution ) . No comparison make Cohorts 1 &amp; 2 Cohort 3 .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tavaborole</mesh_term>
	<criteria>1 . Subjects must meet follow criterion include study : 2 . Witnessed , sign informed consent approve Ethics Committee . 3 . Male female subject race least 18 year age old 65 year age time screen . 4 . For Cohorts 1 2 , subject diagnosis onychomycosis least one great toenail positive KOH wet mount nail . For Cohort 3 , subject must diagnosis onychomycosis least one great toenail positive KOH wet mount AND fungal culture nail . 5 . Onychomycosis involve 2060 % affect great toenail determine visual inspection nail trim . 6 . The combined thickness distal nail plate associate hyperkeratotic nail bed &lt; 3 mm . 7 . Affected great toenail treat capable regrowth document history recent observation least 2 mm growth . 8 . Normal clinically significant screen safety lab . 1 . Females childbearing potential use highly effective method birth control ( e.g . implant , injectables , combine oral contraceptive , intrauterine contraceptive device ) study . 2 . Diabetes mellitus require treatment diet exercise . 3 . Subjects chronic moccasin type T. pedis . 4 . Subjects history fail previous topical antifungal therapy onychomycosis . 5 . Subjects unwilling refrain use nail cosmetic clear color nail lacquer screen visit end study . 6 . Subjects undergone specify washout period ( ) follow topical preparation subject require concurrent use follow topical medication : Topical antifungal apply foot ( include antifungal treatment T. pedis study ) : 4 week Antiinflammatories , corticosteroid , topical immunomodulators : 2 week 7 . Subjects undergone specify washout period ( ) follow systemic medication subject require concurrent use follow systemic medication : Corticosteroids ( include intramuscular injection ) : 2 week Antifungals treatment onychomycosis systemic antifungal know activity dermatophytes : 24 week Systemic immunomodulators : 4 week 8 . Treatment type cancer within last 6 month . 9 . History significant internal disease . 10 . Subjects medical history current past psoriasis skin and/or nail . 11 . Concurrent lichen planus . 12 . Subjects know allergic test product ( ) components test product ( ) history hypersensitivity allergic reaction study preparation describe Investigator 's Brochure . 13 . Nail anatomic abnormality toe , e.g. , genetic nail disorder , primentary disorder , onychogryphosis , trauma nail ( ) treat . 14 . AIDS AIDS relate complex . 15 . History street drug alcohol abuse . 16 . Any subject able meet study attendance requirement . 17 . Subjects participate trial investigational drug device within 60 day prior enrollment participation research study concurrent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Onychomycosis</keyword>
	<keyword>Fungal Nail</keyword>
</DOC>